It has long been understood that psychedelics played a key role in the early digital innovations of Silicon Valley. Today, data and technology are having an equally significant impact in the development of psychedelic medicines.
Join us on 7 October 2021, to discover the cutting-edge technologies and data sciences driving innovation within the burgeoning psychedelic industry. In partnership with Mind Cure and Novamind, thought leaders at the forefront of this crucial – and exponential – period of evolution will discuss:
Leveraging its global network of investors, each PSYCH Investor Summit delivers the industry’s most promising opportunities directly to financiers and funds. Engage with industry leaders, rising entrepreneurs and global psychedelics investors to connect, share insights and help push the market to new frontiers.
Mind Cure combines psychedelic research, technology, and medicines to optimise mental health care for clinicians and their clients.medicine through a network of clinics and clinical research sites.
Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics and clinical research sites.
aNUma creates digital therapeutics at the intersection of psychedelics and virtual reality. Embodied group interaction supports the psychedelic experience, achieving target outcomes more reliably with reduced therapist workload.
Join industry insiders and subscribe for exclusive news, data
and insights from across the psychedelics industry.